Leveraging the profound advances in engineering, medicine, biotechnology and machine learning to transform the way diseases are detected, tracked, treated, and understood.Explore our Technology
Transforming the measurement of disease progression in vivo using noninvasive biosensors.Explore
Bioengineered, tunable sensors that are designed for each protease-mediated disease.Explore
Evolving the way diseases are understood, tracked and treated to accelerate the development of drugs.Explore
At Glympse, we are focused on better understanding diseases to transform disease detection and predict treatment response.Learn about our team
We blend the best of the drug-device development and regulatory pathway, the therapeutics go-to-market model, and a biology-rich data engine.
Our protease activity-based biosensors are accurate, sensitive, specific and measured in a novel noninvasive approach.
We have engineered tunable and specific biosensors to better understand important, complex diseases such as cancer, fibrosis, inflammation, and infections.
By partnering with drug developers, physicians and payers, we can accelerate therapeutic development by rapidly determining patient response to treatment.
With predictive algorithms and machine learning, our technology has a unique approach to capture the biology inside the body and create a map for disease progression.
Glympse cofounder Dr. Sangeeta Bhatia discusses her work transforming the early detection of diseases, like cancer, by leveraging the miniaturization revolution to create ultra-sensitive, bioengineered sensors.